Stock Scorecard
Stock Summary for Vera Therapeutics Inc - Class A (VERA) - $21.88 as of 7/25/2025 1:23:09 PM EST
Total Score
9 out of 30
Safety Score
35 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for VERA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VERA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VERA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for VERA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for VERA (35 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for VERA
Financial Details for VERA
Company Overview |
|
|---|---|
| Ticker | VERA |
| Company Name | Vera Therapeutics Inc - Class A |
| Country | USA |
| Description | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United States. The company is headquartered in South San Francisco, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | 8/7/2025 |
Stock Price History |
|
| Last Day Price | 21.88 |
| Price 4 Years Ago | 26.72 |
| Last Day Price Updated | 7/25/2025 1:23:09 PM EST |
| Last Day Volume | 674,354 |
| Average Daily Volume | 1,208,486 |
| 52-Week High | 51.61 |
| 52-Week Low | 18.53 |
| Last Price to 52 Week Low | 18.08% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 21.96 |
| Sector PE | 41.43 |
| 5-Year Average PE | -11.74 |
| Free Cash Flow Ratio | 25.44 |
| Industry Free Cash Flow Ratio | 17.72 |
| Sector Free Cash Flow Ratio | 32.93 |
| Current Ratio Most Recent Quarter | 27.68 |
| Total Cash Per Share | 0.86 |
| Book Value Per Share Most Recent Quarter | 8.39 |
| Price to Book Ratio | 2.70 |
| Industry Price to Book Ratio | 33.70 |
| Sector Price to Book Ratio | 30.75 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 136.89 |
| Sector Price to Sales Ratio Twelve Trailing Months | 40.01 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 63,774,000 |
| Market Capitalization | 1,395,375,120 |
| Institutional Ownership | 112.50% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -58.50% |
| Reported EPS 12 Trailing Months | -3.00 |
| Reported EPS Past Year | -0.81 |
| Reported EPS Prior Year | -2.75 |
| Net Income Twelve Trailing Months | -175,459,000 |
| Net Income Past Year | -152,148,000 |
| Net Income Prior Year | -95,990,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -91.57% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 55,090,000 |
| Total Cash Past Year | 92,646,000 |
| Total Cash Prior Year | 45,681,000 |
| Net Cash Position Most Recent Quarter | 4,182,000 |
| Net Cash Position Past Year | 41,959,000 |
| Long Term Debt Past Year | 50,687,000 |
| Long Term Debt Prior Year | 49,877,000 |
| Total Debt Most Recent Quarter | 50,908,000 |
| Equity to Debt Ratio Past Year | 0.92 |
| Equity to Debt Ratio Most Recent Quarter | 0.91 |
| Total Stockholder Equity Past Year | 577,155,000 |
| Total Stockholder Equity Prior Year | 101,685,000 |
| Total Stockholder Equity Most Recent Quarter | 534,999,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -205,978,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.23 |
| Free Cash Flow Past Year | -135,651,000 |
| Free Cash Flow Prior Year | -92,244,000 |
Options |
|
| Put/Call Ratio | 1.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.05 |
| MACD Signal | 0.09 |
| 20-Day Bollinger Lower Band | 18.31 |
| 20-Day Bollinger Middle Band | 22.93 |
| 20-Day Bollinger Upper Band | 27.54 |
| Beta | 1.19 |
| RSI | 45.42 |
| 50-Day SMA | 33.63 |
| 150-Day SMA | 25.16 |
| 200-Day SMA | 23.82 |
System |
|
| Modified | 7/24/2025 12:52:15 PM EST |